[{"orgOrder":0,"company":"SK Bioscience","sponsor":"Doherty Institute","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2023","type":"Collaboration","leadProduct":"Quadrivalent Cell Culture-based Influenza Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"SK Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SK Bioscience \/ Doherty Institute","highestDevelopmentStatusID":"2","companyTruncated":"SK Bioscience \/ Doherty Institute"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : SK bioscience and the Doherty Institute will work to support and research in influenza biology, vaccines and antivirals. The program includes testing of anti-influenza compounds to identify new antivirals and development of quadrivalent cell culture-base...

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          June 27, 2023

                          Lead Product(s) : Quadrivalent Cell Culture-based Influenza Vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Discovery

                          Sponsor : Doherty Institute

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Celltrion achieved the first step of developing an antiviral treatment to fight COVID-19 and Plans to launch a fast self-testing diagnostic kit that could provide results within 15-20 minutes.

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          March 23, 2020

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Discovery

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank